Main Topic: The podcast episode discusses the challenges and complexities of distributing COVID-19 vaccines in the US and globally, including allocation, distribution, and verification.
Key Points:
Participants:
Takeaways:
Additional Insights:
Theme music fades out
Noam Hassenfeld
Support for Today Explained comes from Adio. Adio is an AI-native customer relationship management platform that Adio says is built for the next era of companies.
Pause
A powerful data structure adapts to your business model, syncs in all your contacts in minutes, and enriches your business with actionable data. Adio says it also allows you to create those email sequences, those real-time reports, those powerful automations, which they claim can help you build what matters most, your company.
Pause
You can go to adio.com slash todayexplained to get 15% off your first year. That's A-T-T-I-O dot com slash todayexplained.
Pause
Not all journalism is the same. Take The Guardian. Our coverage has something unique, fierce independence. Nobody owns us or tells us what we can and can't say. So we're free to report the whole picture. We connect what's happening in Washington to the rest of the globe, expose corruption wherever we find it, and give first perspective on everything from wellness and soccer to culture, the climate and more.
Pause
Read, watch and listen to The Guardian for free at theguardian.com. The U.S. averaged over 160,000 COVID cases per day during the last two weeks. and that number may rise quickly due to Thanksgiving travel. But we just might be starting to see light at the end of the tunnel.
Pause
In the last few weeks, we've seen three companies, Pfizer, AstraZeneca, and Moderna, release encouraging news about their vaccines. And today, Moderna released the final results of their phase 3 trial, which showed a vaccine that is 94% effective. This is unprecedented. This is the only time this has happened at this speed.
Pause
Dr. Rebecca Weintraub, she heads up the Global Health Delivery Project at Harvard. That we have now three likely candidates, three vaccines that will likely make it through phase three trials. But developing a vaccine is just the first step.
Pause
What might be even harder is actually getting the vaccine into people's arms. Right now, public health leaders need to prepare transparent, evidence-based strategies for three different services. Number one, how will they allocate vaccines? Number two, to actually distribute the vaccines. And then to verify.
Pause
We have to actually, to ensure we understand you're not only eligible, but you've received the full course of your vaccines. Okay, let's start with allocation. Are there certain groups that are going to get this vaccine before others?
Pause
Dr. Rebecca Weintraub
Back in August, the National Academies sat down. We knew from day one we won't have enough vaccine for everyone from the start. We will eventually, hopefully, get there. So that demands some thinking that's based on science, that's based on bioethics and other logistical considerations that who comes first.
Pause
And they established 13 subpopulations that are the most vulnerable to COVID-19. They laid out an order by phases. Phase 1, 2, 3 and 4. First, of course, high risk workers in health care, first responders, high risk individuals with underlying conditions, also older adults.
Pause
Phase 2. That includes K-12 teachers and school staff, as well as critical workers in high-risk settings like the food supply system and public transit. Also people in homeless shelters or group homes and all older adults who don't fit into that phase one category.
Pause
Phase three. That's about 40 to 45 percent of the population. That's young adults, children and workers in industries like colleges and universities, hotels, banks, exercise facilities.
Pause
Finally, phase four covers everybody else, guys. And now the states are interpreting that and will likely see very different implementations across the United States and territories.
Pause
Noam Hassenfeld
OK, how about the second issue you mentioned, distribution? Once the FDA approves a vaccine, how does it actually get to people?
Pause
Dr. Rebecca Weintraub
First, actually, think about this. When there's an emergency use authorization, which is quite unusual, these vaccines have already been manufactured. So they will ship 24 hours after the EUA is established.
Pause
So that means state and local officials need to get ready now for how do they think about the allocation and distribution of COVID-19 vaccines. And if you remember back to September, the CDC director at the time told Congress Somewhere between five and a half and six billion dollars is what I think it going to take to distribute this vaccine And you don't have that money right now No sir And you need it to distribute the vaccine I think it's as urgent as getting these manufacturing facilities up
Pause
Unfortunately, there's been less than 10% of that funding that's been allocated as of November. So right now, the states are scrambling.
Pause
Noam Hassenfeld
The actual distribution of the vaccine will go from the feds shipped directly to the states and territories. Then there's a second parallel process directly to federal entities like the Veterans Association or military bases. And then third, there'll likely be a direct distribution to the three large pharmacy chains, CVS, Walgreens, and Walmart.
Pause
And once these companies figure out allocation and distribution, that still leaves the third issue, verification. So it has not been clear if you'll have to show identification at the point of vaccination.
Pause
Dr. Rebecca Weintraub
Will the vaccinator ask you to identify who you are as an individual or bring any type of formal identification?
Pause
And why I bring this up is if you have to remember that all these vaccines, at least this first generation vaccines, are two-dose vaccines that need to be administered within a certain time frame.
Pause
So we need to be able to remind you to come to the second dose. And that's going to also require digital infrastructure to ensure we're identifying you and reminding you to come back for the second dose of the vaccine.
Pause
Noam Hassenfeld
And I mention that because each of these vaccine candidates has had a different protocol, not only about dose, but about the actual vaccine administration, the time between the two doses.
Pause
So if you are the immunization provider, you're going to have to ensure the person's getting the second dose, for example, within 21 days or 28 days.
Pause
And that in and of itself will require information infrastructure. We're talking mainly about the FDA and Americans, but I imagine to vaccinate a population effectively, you know, diseases don't just stop at borders.
Pause
Dr. Rebecca Weintraub
Unfortunately, what we're seeing today is a form of nationalism. Excess demand and competition for supply is already creating vaccine nationalism and risk of price gouging.
Pause
The nations had said, I will serve my nation first. I will procure the supply that I need to cover my general population. And that has weakened actually global cooperation to think about global allocation.
Pause
This is the kind of market failure that only global solidarity, public sector investment and engagement can solve.
Pause
Noam Hassenfeld
What happens if countries don't work together on this? There is no way at this point, considering our global economy, our global supply chains, to say, I will protect alongside my political borders.
Pause
Dr. Rebecca Weintraub
The virus is apolitical and doesn't know state or national borders. So we'll have reservoirs of disease and then we'll have future outbreaks and the continuation of the pandemic.
Pause
Noam Hassenfeld
It is unclear today the reintroduction of the virus from borders slash transport slash the biology of the virus. And that's actually why the particulars of the vaccine are important.
Pause
Dr. Rebecca Weintraub
So these first vaccines that we're looking at today are effective to protect you as an individual from COVID-19 disease. We don't know yet if it actually will decrease transmission of the virus.
Pause
So you may be protected as an individual, but you need to wear a mask to protect others. And so it'll take us quite some time to really understand the duration of immunity and its ability to decrease transmission.
Pause
Noam Hassenfeld
Have we seen examples in the past where countries have worked together to use vaccination in a responsible way to eradicate disease?
Pause
Dr. Rebecca Weintraub
Yes. And, you know, no, thank you for bringing that up, because it's actually a tremendous concern where if we see those outbreaks, it will actually affect confidence in the vaccine.
Pause
People will say, gosh, why are we seeing a future outbreak? I thought we were vaccinated. And that in and of itself is quite complicated to explain to the general public.
Pause
Noam Hassenfeld
So you're right. So we actually have seen this with the Global Polio Eradication Initiative. They actually generated that type of political will, and they had heads of state sit down with each other to think about how do they procure and allocate the vaccine to where it's needed most.
Pause
Dr. Rebecca Weintraub
That took us decades to get there from the discovery and development of the polio vaccines. And that happened with smallpox too, right? That correct So this is also kind of a story that been decades in the making
Pause
Noam Hassenfeld
And really in the end it was political will to say we need to eradicate and end smallpox which means we need to map smallpox globally and allocate distribute and verify those doses went to those outbreaks as needed
Pause
I know we've been successful in the past here with, you know, large scale efforts at vaccination, but given all these hurdles standing in the way, how confident are you? I mean, are you confident this vaccine is going to get where it needs to go?
Pause
Dr. Rebecca Weintraub
Yes, I am much more confident today than I was 30 days ago. And I think there's going to be an evidence-based approach.
Pause
I think the Biden-Harris COVID-19 committee is focused on how best do we participate in global allocation of the vaccine. And we'll see many different tactics and strategies ahead as of the new year.
Pause
Noam Hassenfeld
More with Rebecca in a minute. I'm Noam Hassenfeld filling in for Sean Ramas for him it's Today Explained
Pause
Support for Today Explained comes from Chime nobody likes fees and complicated banking says Chime And Chime gets that, says Chime.
Pause
Chime is a financial technology company that says they understand that every dollar counts. So when you set up direct deposit through Chime, they say you get access to fee-free features, such as free overdraft coverage, getting paid up to two days early with direct deposit, so much more.
Pause
Chime says with qualifying direct deposits, you can be eligible for free overdraft, up to $200 on debit card purchases and cash withdrawals. Plus, they say you don't need to worry about monthly fees or maintenance fees.
Pause
You can work on your financial goals through Chime today. You can open an account in two minutes at chime.com slash explained. That's chime.com slash explained.
Pause
Chime feels like progress. Chime is a financial technology company, not a bank. Banking services and debit card provided by the Bancorp Bank N.A. or Stride Bank N.A. Members FDIC.
Pause
Spot me eligibility requirements and overdraft limits apply. Timing depends on submission of payment file. Fees apply at out-of-network ATMs.
Pause
Bank ranking and number of ATMs according to U.S. News and World Report 2023. Chime checking account required. This message is brought to you by Apple Card.
Pause
Each Apple product, like the iPhone, is thoughtfully designed by skilled designers. The Titanium Apple Card is no different. It's laser-etched, has no numbers, and it earns you daily cash on everything you buy, including 3% back on everything at Apple.
Pause
Apply for Apple Card on your iPhone in minutes. Subject to credit approval, Apple Card is issued by Goldman Sachs Bank USA, Salt Lake City Branch. Terms and more at AppleCard.com.
Pause
Rebecca, at the end of the day, how many people actually need to get a vaccine? We don't need all Americans or the entire global population to get vaccinated.
Pause
Dr. Rebecca Weintraub
We don't need all Americans or the entire global population to get vaccinated. So the models show we need 70 percent of the population must be immune to terminate transmission.
Pause
So as population immunity climbs, vaccinated individuals may receive some degree of protection as the vaccine is rolled out.
Pause
Noam Hassenfeld
And I imagine not everyone is going to just sign up for new vaccines immediately here. Do we know how many Americans are planning to opt out?
Pause
Dr. Rebecca Weintraub
That is a great question. There's kind of constant polling now, both of the workforce and of subpopulations. Dr. Mack at Morehouse College of Medicine is leading this effort for the NIH to understand that for several populations that are facing considerable vulnerabilities.
Pause
So right now, 40 percent of Americans would not take the COVID-19 vaccine if it was offered today in their local pharmacy.
Pause
Noam Hassenfeld
Okay, so it seems like getting to that 70% threshold isn't exactly going to be easy. How do you reassure some of those people that, you know, don't want the vaccine at first?
Pause
Dr. Rebecca Weintraub
So first, I think we need to acknowledge we're actually in the midst of a pandemic trying to distribute a new product.
Pause
And as a healthcare provider, I hear about people's risks and their worry, their lack of confidence of a new product entering the market, and their safety concerns about vaccines.
Pause
So we really need to think about what is your motivation to protect yourself and others today.
Pause
The second piece which I think is important is we have to acknowledge the effect of public trust because of the politicization of the approval process.
Pause
Way ahead on vaccines. You wouldn't have a vaccine if it weren't for me for another four years because FDA would have never been able to do what they did what I forced them to do
Pause
So we understand when patients are saying I am not sure about this vaccine Our job as a healthcare workforce is actually to communicate that to share with you the data about efficacy and safety
Pause
Noam Hassenfeld
Do you think the government is going to be able to earn that trust back?
Pause
Dr. Rebecca Weintraub
I am optimistic we're going to have a tremendous moment when, for example, there's a photograph of Anthony Fauci getting the vaccine.
Pause
I would have no hesitation to take it, nor would I have any hesitation to recommend it to my family.
Pause
And generationally, for those who've seen him be a public servant for decades through multiple pandemics, I think that'll help instill a sense of this is a safe vaccine for me to take.
Pause
And maybe my parents, my grandparents should actually get the vaccine first.
Pause
Noam Hassenfeld
What about conspiracy theories? I mean, when people are talking about 5G technology causing COVID, how do you combat that?
Pause
Dr. Rebecca Weintraub
I think what is important right now is actually what information do we share and show the public and display.
Pause
And I think there is a role that when we're seeing information that is fabricated to market, to tag it, especially if it's being disseminated via social media platforms, and to counter that with very straightforward, evidence-based information that the public can understand.
Pause
Misinformation originates in your local community and then spreads via private messaging.
Pause
So the World Health Organization created a page of Mythbusters where they actually feature fact-based answers to the most common misconceptions about COVID-19.
Pause
And we're encouraging people to actually go to their site and use that to counter the conspiracy theories in your inbox.
Pause
Noam Hassenfeld
And if it's not about conspiracy theories, you know, if it's just about being scared of a new vaccine, you know, if you have a friend or a sibling or an aunt or an uncle, I mean, what do you say to a person like that who is just kind of generally scared of this whole situation?
Pause
Dr. Rebecca Weintraub
This is a similar message to what Anthony Fauci and others have shared about masking and physical distancing, that in order to protect ourselves and our loved ones, this is the public health playbook.
Pause
This is a standard practice. These are required data sets that many third parties have reviewed for phase one, phase two, phase three trials.
Pause
It's happened faster than ever before, but the quality of the data required, the review process is exactly the same as other products, both treatments and vaccines.
Pause
When we think back to the polio vaccination campaigns. Once the public health service authorizes its release, the polio vaccine can begin to protect American youngsters.
Pause
Pediatricians reminded parents, we want to prevent polio disease in your child.
Pause
And the pediatrician was a trusted advisor to that parent. Make use of increasing supplies of vaccine. Help your child grow up strong and straight, free from crippling polio.
Pause
The I Am Hopeful will be able to reestablish a sense of trust between an individual and their health care provider, an individual and their pharmacist, an individual and their nurse.
Pause
and because that's a longitudinal relationship, they will listen to that local influencer and be willing to get the vaccine to protect themselves and others.
Pause
Noam Hassenfeld
Are you confident? Are you going to get the vaccine once it's approved?
Pause
Dr. Rebecca Weintraub
Absolutely. I am pro-science. I believe in the quality of the data that we're going to see once these phase three trials go out and I recommend the vaccine for my parents and in-laws as well.
Pause
Noam Hassenfeld
Dr. Rebecca Weintraub. She's a professor at Harvard Medical School. Her team created an online tool for states and counties to figure out how to distribute vaccines equitably.
Pause
You can check it out and enter in scenarios yourself by going to covid19vaccineallocation.org. Thank you.
Theme music starts playing